Skip to main content
Premium Trial:

Request an Annual Quote

Daryl Faulkner, Steven M. Paul, Gregory McGuinness, Lee Hood, Ruedi Aebersold, Jan Ellenberg, Ulf Landegren

Daryl Faulkner will take over as president and CEO of Digene, effective Dec. 11. He will also become a member of the diagnostic firm’s board of directors. Faulkner will succeed Evan Jones, a founder of Digene, who is retiring after 16 years with the firm.
 
Faulkner most recently served as senior vice president of global business segments at Invitrogen. He announced late last year that he was retiring from the firm. Faulkner spent eight years with Invitrogen in a number of senior level positions. Previous to Invitrogen, he worked for Abbott Laboratories for 15 years.
 

 
Sigma-Aldrich has elected Steven M. Paul to its board of directors. Paul is executive vice president for science and technology and president of the Lilly Research Laboratories of Eli Lilly.
 

 
NimbleGen Systems has named Gregory McGuinness as vice president of international business. McGuinness previously served as director of European business development for Gene Logic. He also has previously worked for Affymetrix, Stratagene, and Applied Biosystems.
 

 
Cellumen has appointed Lee Hood to its scientific advisory board, the company said last week. Hood is president of the Institute for Systems Biology in Seattle.
 

 
The European Molecular Biology Organization has announced new members including Ruedi Aebersold of the Institute of Molecular Systems Biology in Zurich, Switzerland; Jan Ellenberg of the European Microbiology Laboratory in Heidelberg, Germany; Lee Hood of the Institute for Systems Biology in Seattle; and Ulf Landegren of the Department of Genetics and Pathology at Uppsala University, Sweden.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.